Aug. 24, 2004 — The European Commission has approved for use in the European Union rituximab in combination with chemotherapy for first-line treatment of indolent non-Hodgkin's lymphoma, duloxetine ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results